stockportfolio.pro
ADC Therapeutics SA (ADCT)
Healthcare · Biotechnology · NYSE
ADC Therapeutics SA revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $209.91M | $69.56M | $70.84M | $81.36M |
| Gross profit | $206.61M | $67.03M | $64.89M | $75.56M |
| Net income | $-157.13M | $-240.05M | $-157.85M | $-142.62M |
| Net margin | -74.9% | -345.1% | -222.8% | -175.3% |
Source: ADC Therapeutics SA SEC filings (10-K).
Explore 4 years of ADC Therapeutics SA financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ADCT in your portfolio →
ADC Therapeutics SA financial history by metric
About ADC Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
ADC Therapeutics SA — frequently asked questions
What is ADC Therapeutics SA's revenue?
ADC Therapeutics SA (ADCT) reported revenue of $81.36M for fiscal year 2025, up 14.9% from the prior year, according to its SEC filings.
Is ADC Therapeutics SA profitable?
No — ADCT reported a net loss of $-142.62M in fiscal 2025.
What is ADCT's P/E ratio?
ADC Therapeutics SA trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is ADC Therapeutics SA growing?
ADCT's revenue grew at roughly -27.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does ADC Therapeutics SA have?
As of fiscal year 2025, ADCT carried roughly $115.45M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is ADC Therapeutics SA's gross margin?
ADCT's gross margin was 92.9% in fiscal 2025 — gross profit of $75.56M on revenue of $81.36M.
What is ADC Therapeutics SA's market cap?
ADC Therapeutics SA (ADCT) has a market capitalization of about $136.73M, based on the latest data in our nightly-refreshed cache.
When does ADC Therapeutics SA's fiscal year end?
ADCT's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from ADC Therapeutics SA's official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.